Cannabis and Cancer Cachexia
What the evidence actually says about using cannabis and cannabinoids to treat cancer-related wasting, appetite loss, and weight loss.
Cannabis is widely marketed as a cachexia treatment, but the actual evidence is thinner than dispensary posters suggest. Dronabinol (synthetic THC) has decent data for appetite stimulation, weaker data for weight gain, and was beaten by a steroid in the best head-to-head trial. Whole-plant cannabis has barely been studied for cachexia specifically. If you're a cancer patient who isn't eating, cannabis might help you feel hungrier and enjoy food again — but don't expect it to reverse the underlying wasting. Talk to your oncologist.
Not medical advice
This article is not medical advice. Cancer cachexia is a serious, multifactorial syndrome that can interact dangerously with medications, surgery, and disease progression. Nothing here replaces a conversation with your oncologist, palliative care team, or registered dietitian. If you are considering cannabis or cannabinoid medicines as part of cancer care, tell your treating clinicians — drug interactions and immunosuppression considerations are real.
Plain-language summary
Cancer cachexia is more than just appetite loss. It's a syndrome of involuntary weight loss, muscle wasting, fatigue, and metabolic changes driven by the tumor and the body's inflammatory response to it. Roughly half of advanced cancer patients develop it, and it contributes to a significant share of cancer deaths [1] Strong evidence.
People ask about cannabis for two overlapping reasons: (1) they've lost interest in food and want the well-known appetite-boosting effect of THC, and (2) they're losing weight and hope cannabis will reverse it. The honest answer is that cannabis (or more precisely, THC-based medicines like dronabinol) has reasonable evidence for making people feel hungrier and enjoy food more, but weak and inconsistent evidence for actually reversing weight loss or muscle wasting [2][3] Weak / limited.
That's a meaningful distinction. Feeling like eating is not the same as gaining back lean mass.
What probably works
Subjective appetite stimulation with THC-based agents. Multiple trials of dronabinol (synthetic oral THC) in cancer and HIV-associated wasting show improved self-reported appetite and food enjoyment [2][3][evidence:strong for appetite; weak for weight].
Symptom relief that indirectly helps eating. Cannabis and cannabinoids have moderate evidence for chemotherapy-induced nausea and vomiting (CINV) [4] Strong evidence. If nausea is the reason you can't eat, treating the nausea — with cannabinoids or, more often, with standard antiemetics like ondansetron — addresses the root cause.
Improved taste and food enjoyment. A small randomized trial by Brisbois et al. in advanced cancer patients found THC (2.5 mg twice daily) improved chemosensory perception, food enjoyment, and protein intake compared to placebo [5] Weak / limited. The sample was small (n=21 completers) but the result is consistent with patient reports.
What might work
Quality of life and mood in advanced disease. Cannabis is plausibly useful for the cluster of symptoms — pain, anxiety, sleep, anorexia — that accompany advanced cancer. The CAMPCAN and similar observational studies suggest some patients report broad symptom improvement [6] Weak / limited.
Whole-plant cannabis (smoked, vaporized, or oil) specifically for cachexia. Despite enormous patient interest, there are very few rigorous trials of inhaled or whole-plant cannabis for cachexia endpoints. Most evidence is extrapolated from dronabinol studies or from anecdote Anecdote. Whether high-CBD or balanced THC:CBD products differ from pure THC for appetite is essentially unstudied.
Modest weight stabilization in some patients. A few small trials and observational series report weight stability rather than gain. This is not nothing in a wasting syndrome, but it's far from a proven effect Weak / limited.
What doesn't work, or has weak evidence
Cannabis extract vs. THC vs. placebo for cachexia. The Cannabis-In-Cachexia-Study-Group trial (Strasser et al., 2006) randomized 243 advanced cancer patients to cannabis extract, THC, or placebo. It was stopped early for futility — none of the cannabinoid arms beat placebo on appetite or quality of life [7][evidence:strong, negative]. This is the largest dedicated cachexia trial and the result was disappointing for cannabis advocates.
Reversing muscle wasting (sarcopenia). Cachexia is fundamentally a catabolic, inflammation-driven loss of skeletal muscle. No cannabinoid has been shown to preserve or restore lean body mass in cancer patients No data. Marketing claims about cannabis 'rebuilding' the body in cachexia are not supported.
Survival benefit. No credible evidence that cannabis or cannabinoids extend survival in cancer cachexia No data.
The 'indica makes you hungry' folklore. The munchies are real, but the indica/sativa label does not reliably predict appetite effects — it's a chemotype and dose question, not a botanical category Disputed. See Indica vs Sativa.
Comparison with standard treatments
The honest comparison: cannabinoids are not first-line for cancer cachexia in any major guideline.
- Corticosteroids (e.g., dexamethasone) reliably stimulate appetite short-term but cause muscle loss, hyperglycemia, and immune suppression with longer use [8] Strong evidence.
- Progestins (megestrol acetate) increase appetite and weight, but the weight gained is largely fat and water, not lean mass, and they carry thromboembolic risk [8] Strong evidence.
- Anamorelin, a ghrelin receptor agonist, improves appetite and lean mass in trials and is approved in Japan; not FDA-approved in the US [9][evidence:strong for appetite/weight; modest effect size].
- Dronabinol vs. megestrol. A head-to-head trial by Jatoi et al. (2002) found megestrol superior to dronabinol for both appetite and weight gain; the combination was no better than megestrol alone [3] Strong evidence.
- Nutritional counseling and resistance exercise have modest but real benefits and minimal downside [10] Strong evidence.
Most guidelines (ESMO, ASCO) recommend a multimodal approach — nutritional support, physical activity, treating reversible symptoms (pain, nausea, depression), and pharmacotherapy if needed — rather than any single appetite drug. Cannabinoids may have a role as adjuncts, especially when nausea, pain, or sleep are also poor.
Risks and interactions
- Cognitive and psychiatric effects. THC can cause confusion, sedation, anxiety, and rarely psychosis, especially in older or frail patients. Cachectic patients are often both Strong evidence.
- Falls. Sedation plus weakness plus low body mass equals fall risk [evidence:weak but plausible].
- Drug interactions. Cannabinoids are metabolized by CYP3A4 and CYP2C9 and inhibit several CYP enzymes. Real interactions exist with warfarin, tacrolimus, and some chemotherapies [11] Strong evidence.
- Smoking is generally inappropriate for cancer patients, especially those with lung involvement or immunosuppression. Edibles and oils avoid combustion but have delayed and unpredictable onset.
- Contamination. Unregulated cannabis products may contain mold (Aspergillus), heavy metals, or pesticides — a real concern for immunocompromised patients [12] Strong evidence.
- Cost and access. In many jurisdictions, medical cannabis is not insurance-reimbursed; dronabinol usually is.
What we don't know
- Whether inhaled or whole-plant cannabis differs meaningfully from oral THC for cachexia endpoints.
- Whether CBD or CBD-dominant products contribute anything to appetite or weight (mechanistically, CBD is not orexigenic and may blunt THC's effect at high doses) Weak / limited.
- Whether cannabis affects the inflammatory drivers of cachexia (IL-6, TNF-α) in a clinically meaningful way in humans No data.
- Optimal dose, timing, and chemotype for different cancer populations.
- Whether combining a cannabinoid with anamorelin, exercise, or omega-3 supplementation produces additive benefit.
These are genuinely open questions. Anyone claiming firm answers is selling something.
Sources
- Peer-reviewed Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncology. 2011;12(5):489-495.
- Peer-reviewed Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Management. 1995;10(2):89-97.
- Peer-reviewed Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical Oncology. 2002;20(2):567-573.
- Book National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017. ↗
- Peer-reviewed Brisbois TD, de Kock IH, Watanabe SM, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Annals of Oncology. 2011;22(9):2086-2093.
- Peer-reviewed Bar-Lev Schleider L, Mechoulam R, Lederman V, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. European Journal of Internal Medicine. 2018;49:37-43.
- Peer-reviewed Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of Clinical Oncology. 2006;24(21):3394-3400.
- Peer-reviewed Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews. 2013;(3):CD004310.
- Peer-reviewed Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncology. 2016;17(4):519-531.
- Peer-reviewed Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition. 2017;36(1):11-48.
- Peer-reviewed Alsherbiny MA, Li CG. Medicinal cannabis-potential drug interactions. Medicines. 2018;6(1):3.
- Peer-reviewed Ruchlemer R, Amit-Kohn M, Raveh D, Hanus L. Inhaled medicinal cannabis and the immunocompromised patient. Supportive Care in Cancer. 2015;23(3):819-822.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Chemotherapy-Induced Nausea and Vomiting — Cannabinoids have real, replicated antiemetic effects in chemotherapy patients, but they'r...
- Cannabis in Palliative Care — What the evidence actually shows about cannabis for symptom relief at the end of life — an...